← Signal Board

Werewolf Therapeutics financial statements

웨어울프 테라퓨틱스NASDAQ:HOWL · Nasdaq · Healthcare · sector #20
$0.9100-1.10%
2026-10-08 close

Werewolf Therapeutics's published financial data is dated 2026-10-04. 2024 revenue was $2M. 2024 operating profit was −$74M.

Reported results

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -8.08
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-8.08
Beneish M-Score
-5.78

No statistical flag

Sloan accrual
-11.29%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioPass
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -2981%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-203.1% → -3933.5%, -3730.4%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-3,933.5%
Interest coverage
-15.9x
Return on equity (ROE)
-96.1%

Operating margin −5pp

Operating loss
Interest coverageBase -15.9x adverse case -15.9x
Return on equity (ROE)Base -96.1% adverse case -107.5%

Revenue −15%

Interest coverage risk
Interest coverageBase -15.9x adverse case -13.5x
Return on equity (ROE)Base -96.1% adverse case -92.2%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -15.9x adverse case -12.9x
Return on equity (ROE)Base -96.1% adverse case -108.8%

Interest coverage limit

Already below the limit by 4,180.5pp

Interest coverage limit at an operating margin of 247%

Interest expense coverage threshold

Werewolf Therapeutics notifications

Quantus Signal · live data · not investment advice · Privacy Policy